Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Novartis Expiry of...

    Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-30T14:08:29+05:30  |  Updated On 2021-08-16T17:05:11+05:30

    New Delhi: The patent protection of blockbuster anti-diabetic drug Vildagliptin manufactured by the Swiss drugmaker, Novartis, will soon expire on December 9, 2019. The expiry is likely to clear the way for other pharma firms eager to unveil the drug and its generic equivalent.


    The competition for the launch of the drug has been fierce, however, Novartis had left no stones unturned to protect its formulation from being infringed. 18 pharma firms alone in the state of Gujarat were halted last year from launching the drug prior to the copyright expiry. Novartis had reportedly sought legal intervention to protect its drug against companies that even planned to launch the drug.


    Also Read: Novartis, Abbott, Emcure face allegations of cartelisation in anti-diabetes drug Vildagliptin


    However, after a span of five months, patented Vildagliptin will become vulnerable and a dozen of companies are reportedly preparing to grab a piece of the action in the increasing Rs 13000 crore diabetes therapy by launching the generic equivalent of Vildagliptin. As per the industry lookouts, companies including Zydus Cadila, Glenmark, Mankind Pharma, US Vitamins, Cipla and Abbott are keen to unveil the drug, reports TOI.


    Vildagliptin is the first (diabetes) medicine whose end-of-patent life will be witnessed by an industry. It has about 25% share of the gliptins market of Rs 3500 crore. Gliptins, a relatively new class of oral diabetes drug, has emerged as a popular therapy and are contemplated to be the future of treatment.


    The introduction of a generic version of the drug will reportedly cut the cost of the therapy by more than 50%, making it affordable for millions of diabetics. The price of the drug may settle around just Rs 10 for a days therapy which is currently priced as Rs 45. More patients will be drawn in advanced Gliptin therapy as the cheaper version will hit the market.


    Commenting on the expiry of the drug, a Novartis spokesperson told TOI, "We believe the re-continues to be a huge unmet need in this segment. We are unable to share our plans post-patent expiry, as this is competitive information."


    Talking to the daily, Mankind Pharma director Arjun Juneja said, "We have a strategic plan to enter this market. Our current diabetes and metabolic portfolio comprise of all major oral antihyperglycemic agents (OHAs) including Teneligliptin. However it is important to have a molecule in our portfolio which is highly potent, has strong scientific evidence-based efficacy and safety data."

    Abbott anti diabetes drug best diabetes drug blood sugar Cipla diabetes diabetes drug diabetes drug price diabetes in India diabetes patients diabetics Glenmark Gliptins Mankind Pharma Novartis patent patent expiry pharma pharma news pharma news india Teneligliptin Vildagliptin Zydus Cadila 
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X